Registered forecast

20% registered probability event by 2027-03-10 Unresolved

NICE publishes technology appraisal guidance on Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] on or before 2027-03-10

FF-068 Registered Unresolved
registered due
Our estimate
20%
an estimate, not a reading
Action by
2027-03-10
known at this date
Reading window
2026-11-11 → 2027-03-10
known at this date
Decision stage
  1. 5 Guideline
  2. 6 Regulatory
  3. 7 Coverage
Baselines it has to beat
  • Authority base rate 50%
  • Calendar cycle 55%
  • Analyst proxy 20%
  • Known at this date
  • The registered estimate, uncertain
  • Not yet knowable at this date

At this date the record was registered at 20% and the deadline had not been reached. The outcome was not yet knowable.

The outcome is not yet knowable at this date.

nextconsensus.com/forecast/ff-068/ registry snapshot 2026-11-21 Share image

NextConsensus registered this probability on 2026-11-10. It is one of 28 registered NICE scheduled-date forecasts.

The proposition

What was registered

NICE publishes final technology appraisal guidance for the appraisal 'Zilucoplan for treating antibody positive generalised myasthenia gravis' [ID4008], with a publication date on or before 2027-03-10, the expected publication date shown on its in-development page (https://www.nice.org.uk/guidance/indevelopment/gid-ta11096) on 2026-11-10.
Who decides
National Institute for Health and Care Excellence (NICE), Technology Appraisal Committee B (England)
Who has to act
Rung 7: Payer/coverage action — NCD, LCD, formulary change, step-therapy revision, or access expansion/restriction by CMS, MACs, or major commercial payers.
Counted with
NICE guidance by scheduled date
Scope
Antibody-positive generalised myasthenia gravis

The estimate

Our estimate and what it has to beat

20% our estimate, method v0.1.0 · frozen at the 2026-11-10 cutoff

The estimate that the named body takes the action by the deadline, from what was public at the cutoff.

The alternatives it was registered against, each with the reasoning that produced it. They were set at registration: how often this kind of decision happens on time, what the calendar alone suggests, and a reading of the same public record without this method. Each one's reasoning shows whether it is a count of past decisions or an estimate.

Authority base rate 50%

ESTIMATE FROM THE SHAPE OF THE CLASS, NOT AN ENUMERATED COUNT. The share of NICE technology appraisals published on or before the expected date shown at the cutoff is not yet counted; the calendar's census will count it. Expected dates are revised often, most when a committee meeting does not reach a final recommendation, an appeal is lodged or a company asks for time.

Calendar cycle 55%

A clock-only model: a fifth committee meeting on 7 January 2027, 62 days before the expected date, is treated as on schedule: the model assumes final draft guidance and an appeal period fit in that time.

Analyst proxy 20%

An analyst reading the project page, documents and third draft guidance on 2026-11-10 would weigh a narrowed targeted consultation and a meeting NICE has scheduled, against a negative third draft, an appraisal that has slipped repeatedly since 2023, and stakeholders who appealed the last final draft guidance and won a point. Estimated by reconstructing that read, not by surveying analysts.

Technology appraisal (NICE): offered on judgment, with no calibration figure until 15 in the class have resolved.

The method and every record are public, so you can check the work.

The clock

Dates that constrain the record

Evidence as of
2026-11-10
Nothing after this date informed the estimate. known at this date
Registered
2026-11-10
Frozen and hashed. known at this date
Reading window
2026-11-11 → 2027-03-10
When the outcome can be read against the rule. known at this date
Event by
2027-03-10
The final qualifying action date; the frozen resolution rule defines what counts. Add to calendar known at this date
ledger d6edcf42d2f40c3ae94952cd258cf32d85a2f806462cb557d3e2ac73ca48eb08
· operator record jc-1794354012321-658b9c2d

Around this record

Confidential Asset & Milestone Evaluation

Evaluating an asset or milestone that NICE could move?

Name the asset, the deciding authority, and the date your team prepares for: a P&T review, an HTA submission, a label negotiation, a deal closing, or a milestone dispute. It can be an asset you sponsor, evaluate, finance, advise on, or rely on. Every commercial evaluation applies the same pre-registration standard and primary-source verification as this record, delivered privately under mutual NDA.

$9,500 · 10 business days One milestone, authority, and target date: the dated evidence baseline, authority divergence redline, evidence stall assessment, and transition probability. Delivered within ten business days of the kickoff call, or you don't pay.
Under mutual NDA Held to the same standard as this public record: who decides, the resolution rule, and the baselines.
Reconstructing a record? For an earnout, milestone dispute, or expert report: the $5,000 Historical Evidence-State Dossier, one proposition at one cutoff, 5 business days, no probabilities. For an asset's whole history across the class: the $35,000 Regulatory & Coverage Diligence Dossier, 15 business days.

Resolution

How we’ll check the result

Resolves YES if the NICE technology appraisal guidance page published from project ID4008 shows a publication date ('Published: <date>') on or before 2027-03-10, whatever the guidance recommends. The adjudicator finds the page from the in-development page above, which links to or redirects to the published guidance, or by searching nice.org.uk for ID4008. Resolves NO if the guidance is published after 2027-03-10, if the expected date is revised and nothing is published by 2027-03-10, if the appraisal is paused or suspended past that date, or if it is terminated. A terminated appraisal stays in the denominator and resolves NO, as the calendar's rule for this class says. Resolves cancelled_external only if NICE removes the appraisal from its work programme without publishing anything. The frozen date is the one archived at the cutoff; a later revision does not move it. Read no earlier than 2027-03-17. The recommendation itself is a different question and is not scored here. Resolves VOID, with the reason recorded, only if NICE stops publishing technology appraisal guidance pages with publication dates, so that no publication date for this appraisal can be read from nice.org.uk or its successor; while a publication date can be read, the rule stands.
The rule as registered
Resolves YES if the NICE technology appraisal guidance page published from project ID4008 shows a publication date ('Published: <date>') on or before 2027-03-10, whatever the guidance recommends. The adjudicator finds the page from the in-development page above, which links to or redirects to the published guidance, or by searching nice.org.uk for ID4008. Resolves NO if the guidance is published after 2027-03-10, if the expected date is revised and nothing is published by 2027-03-10, if the appraisal is paused or suspended past that date, or if it is terminated. A terminated appraisal stays in the denominator and resolves NO, as registry/CALENDAR.md's rule for this class says. Resolves cancelled_external only if NICE removes the appraisal from its work programme without publishing anything. The frozen date is the one archived at the cutoff; a later revision does not move it. Read no earlier than 2027-03-17. The recommendation itself is a different question and is not scored here. Resolves VOID, with the reason recorded, only if NICE stops publishing technology appraisal guidance pages with publication dates, so that no publication date for this appraisal can be read from nice.org.uk or its successor; while a publication date can be read, the rule stands.

Source the rule names: https://www.nice.org.uk/guidance/indevelopment/gid-ta11096, https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance

After the deadline, the founder (Kanav Jain) reads the outcome against the frozen public source; unratified automated readings are labelled machine-resolved and excluded from class calibration figures.

What this record will show once it resolves

Beside every result, the count for its class (NICE guidance by scheduled date): registered, resolved, unresolved, and expired. One forecast is one instance, not a rate.

The finding
As the rule above reads it: occurred on time, did not occur, or left unscored.
The readers and their sources
After the deadline, the founder (Kanav Jain) reads the frozen public source named above under the registered rule (or automated checks record a machine-resolved reading). Who adjudicated it and the source read are published here so any reader can verify the outcome. Adjudication applies the frozen rule to the named public source so any reader can verify the reading independently.
The number against its baselines
20% beside three baselines, each scored by the same rule (squared error), so a reader can see how the record did against each of them.

Email me when FF-068 resolves

One email when the result is published, then nothing; the address is deleted a month later.

Reasoning

What the number rests on

The facts it was built from are below, as they stood at the cutoff, with every source archived; each baseline above carries the reasoning that produced it. The written mechanism and the conditions that would make the proposition ill-posed were frozen with the record, are held in the ledger, and are covered by its hash.

The state of the record at the cutoff

Recorded as they stood on 2026-11-10.

review pathway
STA Standard by Technology Appraisal Committee B (enquiries to TACommB) (SRC-001)
submission type
New appraisal, remitted to committee after an upheld appeal point (appeal decision 28 January 2026); company UCB Pharma (SRC-001, SRC-002).
evidence class
not applicable — the proposition is a publication date, not an evidence judgement
pivotal n
not applicable
endpoint type
not applicable — the proposition is a publication date
approved competitors in class
Comparator companies on the project page include Alexion (ravulizumab) and argenx (efgartigimod); standard treatment named in the draft guidance is thymectomy, acetylcholinesterase inhibitors, corticosteroids and non-steroidal immunosuppressants, with intravenous immunoglobulin or plasma exchange (SRC-001, SRC-003).
months since last guideline revision
not applicable
panel cycle position
Committee meetings 1 to 4: 13 June 2024, 09 October 2024, 05 February 2025, 17 June 2026; draft guidance 3 consultation 07-28 August 2026; committee meeting 5 scheduled 07 January 2027, 62 days before the expected publication date of 10 March 2027 (SRC-001, SRC-003). The committees page lists Committee B meetings only to 10 December 2026 (SRC-004).
sponsor request status
No company request for more time or pause is recorded on the project page; NICE asked the company for further evidence after the appeal (SRC-001).
odac referral
not applicable — NICE committee, not an FDA advisory committee
sponsor state change
none recorded in the archived sources

Sources

Everything the estimate was built from

Each was retrieved on or before the 2026-11-10 cutoff and archived at the digest shown. If a publisher edits a page after the fact, the digest stops matching and the substitution is visible.

  1. SRC-001 NICE in-development page (Project information tab) for GID-TA11096. Shows 'Expected publication date: 10 March 2027', status 'In progress', 'Process: STA Standard', provisional schedule (committee meeting 5: 07 January 2027; expected publication 10 March 2027), company UCB Pharma, enquiries to TACommB, and the timeline: committee meetings 13 June 2024, 09 October 2024, 05 February 2025 and 17 June 2026; draft guidance consultations July 2024, November-December 2024 and 07-28 August 2026; final draft guidance 26 June - 10 July 2025; appeal 22 August 2025; appeal decision 28 January 2026; a note of 08 April 2026 that, following an upheld appeal point, the appeal panel remitted the final draft guidance to committee.

    https://www.nice.org.uk/guidance/indevelopment/gid-ta11096

    Retrieved 2026-11-10 · sha256 ea782a3b6e552ca5e7a407e04c83e0f6c8806cd467963478af8b66e9d0d89ca8

  2. SRC-002 NICE Project documents tab for GID-TA11096. Lists draft guidance 3 with committee papers and slides (published 07 August 2026); four appeal letters with scrutiny letters (published 19 November 2025) and the appeal decision (28 January 2026); the final draft guidance of 26 June 2025; draft guidance 2 (14 November 2024) and 1 (04 July 2024); no final guidance listed.

    https://www.nice.org.uk/guidance/indevelopment/gid-ta11096/documents

    Retrieved 2026-11-10 · sha256 92f275f613925ebd92acb6f266eddb7c9ace856ad127d8672b69b73a6f9877d1

  3. SRC-003 Draft guidance consultation 3 PDF (issue date July 2026). Recommendation 1.1: zilucoplan should not be used as an add-on to standard treatment for generalised myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies. A targeted consultation on 4 remaining uncertainties (minimal symptom expression in the model, plasma exchange administration costs, rates of exacerbations and myasthenic crises, and their costs); closing date 28 August 2026; evaluation committee meeting TBC; the final draft guidance is subject to appeal.

    https://www.nice.org.uk/guidance/gid-ta11096/documents/consultation-document

    Retrieved 2026-11-10 · sha256 dad7eca99a7ccf6b7ab5f9ea6d822e3e52837716647d2b2d37bba06e58d12b6b

  4. SRC-004 NICE Technology appraisal committees page, retrieved 2026-11-10. Lists next meeting dates for Committees A to D through December 2026, including Committee B on 15 October, 12 November and 10 December 2026; no 2027 date is listed.

    https://www.nice.org.uk/get-involved/our-committees/nice-committee-meetings/technology-appraisal-committees

    Retrieved 2026-11-10 · sha256 5f7e953ea377383b9a7e6119345c399f25f0458952a201d5383b23599b088491